Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 372 (9647), 1394-1402
- https://doi.org/10.1016/s0140-6736(08)61412-9
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Fear of visual loss in patients with diabetes: results of the Prevalence of Diabetic Eye Disease in Tayside, Scotland (P‐DETS) studyDiabetic Medicine, 2007
- Inhibiting the renin–angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trialsCurrent Opinion in Cardiology, 2006
- Feasibility of Treating Prehypertension with an Angiotensin-Receptor BlockerNew England Journal of Medicine, 2006
- Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen)Diabetes & Metabolism, 2005
- The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristicsJournal of the Renin-Angiotensin-Aldosterone System, 2005
- Generalized Log-Rank Tests for Interval-Censored Failure Time DataScandinavian Journal of Statistics, 2005
- The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study designJournal of the Renin-Angiotensin-Aldosterone System, 2002
- UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosisDiabetologia, 2001
- A Hybrid Algorithm for Computation of the Nonparametric Maximum Likelihood Estimator from Censored DataJournal of the American Statistical Association, 1997
- Impaired Retinal Artery Blood Flow in IDDM Patients Before Clinical Manifestations of Diabetic RetinopathyDiabetes Care, 1995